Fly News Breaks for February 24, 2020
Feb 24, 2020 | 06:39 EDT
Chardan analyst Geulah Livshits initiated coverage of Homology Medicines (FIXX) with a Buy rating and $34 price target. In a research note to investors, the analyst says that while HMI-102 faces competition from assets in development by BioMarin (BMRN) and others, she believes Homology's potentially-registrational trial design and internal manufacturing capabilities position the company to move quickly. Homology is well positioned to advance its internal programs, Livshits says, adding that the company does not need gene editing to work in order to see upside.
News For FIXX;BMRN From the Last 2 Days